• In early May 2026, Lockheed Martin secured a series of defense wins and corporate developments, including U.S. Space Force work on the Space-Based Interceptor program, a new modular 5G solution for U.S. and allied forces announced by Nokia Federal Solutions and Lockheed Martin, and the planned June 1 leadership transition as Orlando “OJ” Sanchez Jr. takes over the US$30 billion Aeronautics segment while Greg Ulmer shifts to a strategic advisory role.
• Together, these contract awards, technology collaborations, and leadership changes reinforce Lockheed Martin’s role across missile defense, secure communications, and advanced aircraft programs at a time of elevated global defense demand.
• We’ll now examine how the new Space-Based Interceptor work and 5G defense collaboration affect Lockheed Martin’s existing investment narrative.

Find 44 companies with promising cash flow potential yet trading below their fair value.

Lockheed Martin Investment Narrative Recap

To own Lockheed Martin, you need to believe its deep backlog, missile defense franchises, and combat aircraft programs can offset cost, execution, and budget risks. The recent Space-Based Interceptor (SBI) win and Nokia 5G collaboration support the near term catalyst of sustaining high value U.S. and allied contracts, but they do not remove the key risk around fixed price program overruns and potential future charges that could pressure margins and earnings expectations.

The SBI award from the U.S. Space Force is the most relevant development here, because it ties directly into Lockheed Martin’s missile defense and space portfolio that many investors already view as central to the thesis. While this work reinforces the idea of a layered homeland defense architecture, it also increases Lockheed Martin’s exposure to technically complex programs where design, integration, and test issues have previously driven large charges, which matters for how you think about future profitability and cash flows.

Yet behind the contract wins and leadership changes, investors should also be aware of how renewed cost overruns or fresh reach forward losses could still...

Lockheed Martin's narrative projects $87.8 billion revenue and $8.0 billion earnings by 2029. This requires 5.4% yearly revenue growth and about a $3.2 billion earnings increase from $4.8 billion today.

Uncover how Lockheed Martin's forecasts yield a $637.60 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most bearish analysts were assuming only about 3.1 percent annual revenue growth to roughly US$82.2 billion by 2029 and earnings of about US$7.6 billion, so if you are worried about cost overruns on programs like SBI this more cautious narrative may feel closer to your own expectations and it is worth exploring how new awards could shift those assumptions.

Explore 13 other fair value estimates on Lockheed Martin - why the stock might be worth just $499.55!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Lockheed Martin research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lockheed Martin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lockheed Martin's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.